Atom Bioscience

Chronic gout
#Atom Bioscience #China #Clinical trial #Gout #hyperuricemia #Phase II trial

URAT1 inhibitor controls chronic gout at low doses

Atom Bioscience has revealed positive results from its China Phase IIa clinical trial of ABP-671, its URAT1 inhibitor for chronic gout.  The randomised, double-blind, placebo-controlled trial enrolled 54 patients with gout or  across six cohorts, with seven randomised to ABP-671 and two to placebo per cohort. … Read More

#News